|
Characteristics
|
Total(n = 260)
|
EBV-positive(n = 16)
|
EBV-negative(n = 244)
|
P value
|
|---|
|
No.
|
%
|
No.
|
%
|
No.
|
%
|
|---|
|
Sex(male/female)
|
260(157/103)
|
16(11/5)
|
244(146/98)
|
0.492
|
|
Age(y) median(range)
|
55(15–85)
|
58.5(38–84)
|
55(15–85)
| |
|
Subgroup
|
|
GCB
|
66/176
|
37.5
|
5/15
|
33.3
|
61/161
|
37.9
|
0.727
|
|
non-GCB
|
110/176
|
63.5
|
10/15
|
66.7
|
100/161
|
62.1
|
|
Initial Chemotherapy
|
|
R-CHOP
|
162/260
|
62.3
|
8/16
|
50.0
|
154/244
|
63.1
|
0.294
|
|
CHOP
|
69/260
|
26.5
|
4/16
|
25.0
|
65/244
|
26.6
|
0.886
|
|
other
|
18/260
|
6.9
|
1/16
|
6.3
|
17/244
|
7.0
|
0.913
|
|
no treatment
|
11/260
|
4.2
|
3/16
|
18.8
|
8/244
|
3.3
|
0.003
|
|
Therapeutic response
|
|
CR
|
108/228
|
47.6
|
2/12
|
16.7
|
106/216
|
49.1
|
0.029
|
|
PR
|
45/228
|
19.8
|
4/12
|
33.3
|
41/216
|
19.0
|
0.224
|
|
SD
|
4/228
|
1.8
|
0/12
|
0.0
|
4/216
|
1.9
|
0.634
|
|
PD
|
71/228
|
31.3
|
6/12
|
50.0
|
65/216
|
30.1
|
0.147
|
|
Clinical stage
|
|
I
|
32/251
|
12.7
|
1/15
|
6.7
|
31/236
|
13.1
|
0.466
|
|
II
|
39/251
|
15.5
|
1/15
|
6.7
|
38/236
|
16.1
|
0.328
|
|
III
|
58/251
|
23.1
|
0/15
|
0
|
58/236
|
24.6
|
0.029
|
|
IV
|
122/251
|
48.6
|
13/15
|
86.7
|
109/236
|
46.2
|
0.002
|
|
B symptoms present
|
95/260
|
36.5
|
10/16
|
62.5
|
85/244
|
34.8
|
0.026
|
- CR Complete remission, PR Partial remisssion, SD Stable disease, PD Progression of disease, R Rituximab
- P values are for the comparison of EBV+ and EBV─DLBCL patients
